Research advances on EGFR-targeted therapy and acquired resistance in nonsmall cell lung cancer
10.3969/j.issn.1000-8179.2017.23.129
- VernacularTitle:非小细胞肺癌EGFR靶向治疗和继发耐药机制的研究进展
- Author:
LI CHENGUANG
1
Author Information
1. 天津医科大学肿瘤医院肺部肿瘤科
- Keywords:
NSCLC;
EGFR;
targeted therapy;
acquired resistance
- From:
Chinese Journal of Clinical Oncology
2017;44(23):1212-1216
- CountryChina
- Language:Chinese
-
Abstract:
Non-small cell lung cancer (NSCLC) is the most common subtype of lung cancer. Small molecular drug therapy that targets epidermal growth factor receptor (EGFR) has significantly improved the survival and quality of life of patients with advanced NSCLC. However, almost all of these patients experience drug resistance. Despite research advances, some of the molecular mechanisms un-derlying acquired remain unknown. This review focuses on recent studies on EGFR mutations, clinical trials of EGFR-targeted drugs, and research on the mechanisms and therapies of acquired resistance. Several molecular testings are needed to clarify the mechanism underlying acquired resistance to achieve personalized care of these patients.
